ESR1 and breast carcinoma: Using the overall, ER-positive, and ER-negative breast cancer PRSs developed by Mavaddat, the per SD hazard ratio estimates in mutation carriers were smaller than the corresponding per SD odds ratio estimates for breast cancer in the population-based study (20).